Oppenheimer Maintains Outperform on Crinetics Pharmaceuticals, Raises Price Target to $46
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Leland Gershell maintains an Outperform rating on Crinetics Pharmaceuticals (NASDAQ:CRNX) and raises the price target from $40 to $46.
September 11, 2023 | 2:17 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Crinetics Pharmaceuticals' price target has been raised from $40 to $46 by Oppenheimer, maintaining an Outperform rating.
The raised price target and maintained Outperform rating by Oppenheimer indicates a positive outlook for Crinetics Pharmaceuticals. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100